Hosted by China Pharmaceutical Innovation and Research Development Association (PhIRDA), China BioMed Innovation and Investment Conference (CBIIC) is a high-level platform encouraging conversation between domestic and foreign pharmaceutical, biotech, and investment companies.
CBIIC aims to be an international, authoritative and diversified platform for analyzing pharmaceutical innovation policies in China and publicizing the achievements of pharmaceutical innovation and investment trends at home and abroad.
The 2019 CBIIC is an opportunity for professionals to foresee the newest trends in pharmaceutical R&D, discover potential high-value projects, explore new ways of pharmaceutical investment, and discuss new strategies for innovative cooperation.
Some of the forum topics will include:
How will the SSE STAR Market Become the Next Nasdaq
Empowerment of Hong Kong Capital Market in Biotech’s Growth
Legal Issues and Opportunities in Cross-Border Biotech Deals
Review and Approval Standards of Orphan Drugs
Clinical Trial Data Releases
Some of the panelists and speakers include:
Liu Yongjun, Global Head of Research, Sanofi
Charles Li, Chief Executive of Hong Kong Exchanges and Clearing Limited (HKEX)
Founded in 1988, China Pharmaceutical Innovation and Research Development Association (PhIRDA) is registered as a non-profit organization by the Ministry of Civil Affairs of China at the first national level. PhIRDA focuses its efforts on academia-industry collaboration, which centers on the principle of “innovation, industrialization, and internationalization,” and persists in innovation to achieve unmet clinical requirements. At its current stage, PhIRDA has 144 members.